AlaMab is a clinical stage biopharmaceutical company focused on commercializing novel, first-in-class monoclonal antibody therapeutics to benefit patients suffering from indications with significant unmet treatment needs.

We are currently conducting Phase I trials on two programs, ALMB-0166 for acute spinal cord injury.
(SCI) and ALMB-0168 for bone tumors, particularly osteosarcoma. Both candidates have received Orphan Disease Drug status and ALMB-0168 has also been granted Rare Pediatric Disease status for its potential as a treatment for osteosarcoma.

AlaMab Therapeutics is proud to have the following investment partners:

For AlaMab Therapeutics investment or partnering inquiries,  please contact us at